Form 4: LeMaitre Vascular Insider Dividend Accrual
Statement of Changes in Beneficial Ownership
President and Director David B. Roberts reported the accrual of dividend equivalent rights on existing equity awards.
Summary
- David B. Roberts, President and Director of LeMaitre Vascular, Inc., reported the acquisition of 22.5718 dividend equivalent rights.
- These rights accrued on various restricted stock unit (RSU) and performance share unit (PSU) awards granted between 2022 and 2025.
- Each dividend equivalent right represents the economic equivalent of one share of common stock and vests proportionately with the underlying awards.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing with no impact on the company's fundamental valuation or strategic direction.
Positives
- Reflects ongoing alignment between executive compensation and shareholder dividends.
- Demonstrates continued accumulation of equity-based incentives by senior leadership.
Negatives
- None identified; this is a routine administrative disclosure of dividend accruals.
Risks
- Value of these rights is tied to the future performance and vesting conditions of the underlying RSU and PSU awards.
Future Outlook
The rights will vest in accordance with the vesting schedules of the original RSU and PSU awards to which they are attached.
Industry Context
StockSavvy.ai notes that this filing is a standard regulatory disclosure regarding executive equity compensation and does not signal a change in corporate strategy or market outlook.
Comparison to Industry Standards
- Consistent with standard executive compensation practices for publicly traded medical device companies.
- Dividend equivalent rights are a common mechanism to ensure executives are not economically disadvantaged by dividend payments prior to the vesting of their equity awards.
Stakeholder Impact
- Minimal impact on shareholders as this represents the standard accrual of existing compensation packages.
Next Steps
- Vesting of underlying RSU and PSU awards according to their respective grant agreements.
Key Dates
| Date | Description |
|---|---|
| 12/12/2022 | Grant date of initial RSU and PSU awards. |
| 12/08/2023 | Grant date of subsequent RSU and PSU awards. |
| 12/06/2024 | Grant date of subsequent RSU and PSU awards. |
| 02/18/2025 | Grant date of subsequent RSU and PSU awards. |
| 12/10/2025 | Grant date of subsequent RSU award. |
| 06/04/2026 | Transaction date for dividend equivalent rights accrual. |
| 06/05/2026 | Filing date of the Form 4. |
Keywords
LeMaitre Vascular, LMAT, Insider Trading, Dividend Equivalent Rights, Executive Compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.